Engineered Antibodies to Improve Efficacy against Neurodegenerative Disorders

Sarfaraz K. Niazi,Zamara Mariam,Matthias Magoola

DOI: https://doi.org/10.3390/ijms25126683

IF: 5.6

2024-06-19

International Journal of Molecular Sciences

Abstract:Antibodies that can selectively remove rogue proteins in the brain are an obvious choice to treat neurodegenerative disorders (NDs), but after decades of efforts, only two antibodies to treat Alzheimer's disease are approved, dozens are in the testing phase, and one was withdrawn, and the other halted, likely due to efficacy issues. However, these outcomes should have been evident since these antibodies cannot enter the brain sufficiently due to the blood–brain barrier (BBB) protectant. However, all products can be rejuvenated by binding them with transferrin, preferably as smaller fragments. This model can be tested quickly and at a low cost and should be applied to bapineuzumab, solanezumab, crenezumab, gantenerumab, aducanumab, lecanemab, donanemab, cinpanemab, and gantenerumab, and their fragments. This paper demonstrates that conjugating with transferrin does not alter the binding to brain proteins such as amyloid-β (Aβ) and α-synuclein. We also present a selection of conjugate designs that will allow cleavage upon entering the brain to prevent their exocytosis while keeping the fragments connected to enable optimal binding to proteins. The identified products can be readily tested and returned to patients with the lowest regulatory cost and delays. These engineered antibodies can be manufactured by recombinant engineering, preferably by mRNA technology, as a more affordable solution to meet the dire need to treat neurodegenerative disorders effectively.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problem this paper attempts to address is the poor efficacy of antibody treatments in neurodegenerative diseases (NDs). Specifically, despite decades of effort, currently only 2 antibodies have been approved for the treatment of Alzheimer's disease (AD), and many other antibodies have encountered difficulties or failures in clinical trials. The main reason is that these antibodies cannot effectively cross the blood-brain barrier (BBB), resulting in insufficient concentrations in the brain to produce therapeutic effects.

The paper proposes a solution by enhancing the ability of antibodies to cross the blood-brain barrier through conjugation with transferrin. This method not only improves the efficiency of antibody entry into the brain but also ensures that the antibody fragments remain connected after entering the brain through specific design, thereby optimizing their binding to target proteins such as β-amyloid (Aβ) and α-synuclein (α-synuclein). Additionally, this method allows for the recombinant engineering of these engineered antibodies, particularly using mRNA technology, to meet the urgent need for treating neurodegenerative diseases in a more cost-effective manner.